VXRT - Did You Miss Out on a 2000% Gain with Vaxart Stock?
Investors have awarded Vaxart (NASDAQ: VXRT) for its innovation this year. Like more than 50 other companies, Vaxart is developing a potential coronavirus vaccine. But its vaccine doesn't involve a jab; it's a tablet to be taken orally. Shares rose as the company announced its development of the vaccine and investors hoped it might be included in a list of vaccine developers to receive government funding.
The government didn't fund Vaxart's program -- at least not so far. But the company has advanced its vaccine candidate into human trials. You may have missed out on Vaxart's 2,105% gain this year if you didn't invest in the shares in the first quarter. But if its investigational vaccine is successful, there may be more share performance like that on the horizon.
Image source: Getty Images.
For further details see:
Did You Miss Out on a 2,000% Gain with Vaxart Stock?